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In recent years, the field of intensive care medicine has had
the benefit of learning from two randomized controlled trials
that tight glycemic control (TGC) is beneficial to critically ill
patients [1,2]. No benefit was found by two other clinical
trials, however, hampering implementation of TGC in daily
practice [3,4]. The question arises of whether the intensive
care community interprets the results of these later trials in
the correct way. What are the alternative explanations for why
two trials do show beneficial effects while two other trials do
not, apart from the possibility that TGC may indeed not
benefit critically ill patients?
The authors of the recently published trial recognize several
shortcomings of their study [4]. Indeed, De la Rosa and
colleagues observed a large variability of blood glucose levels
in their study. This study may therefore simply have been under-
powered to show any beneficial effect of TGC. Apart from this
concern, two issues pertain to the comparability of the studies.
First, the delay in recruitment, much longer than in the original
studies [1,2], may also explain their findings as it is possible
that any benefit of TGC can be accrued only early on.
Second, we would like to identify the crucial issue of the
insulin dosing in the control group. An increasing number of
patients in the control groups of the first three trials were
receiving insulin, from 39% in the first trial [1] to 70% and
74% in the second trial and third trial, respectively [2,3]. This
difference may explain the decrease in relative benefit of TGC
with each consecutive trial: while the first trial showed a
mortality reduction with TGC in all patients [1], improved
survival was only found in patients with a prolonged length of
stay in the second trial [2], while no beneficial effect at all
was seen in the last trial [3]. In the recently published trial of
De la Rosa and colleagues, 47% of patients in the control
group received insulin [4]. This finding not only illustrates
nicely that (some sort of) glycemic control already found its
way into daily care during conduct of the newer studies, but
may also have diluted the beneficial effect of TGC.
If we agree that evidence-based medicine seeks to apply
judgments about the quality of evidence, the evidence that
derives from confirmation trials should be properly judged
too, as in the initial studies – otherwise we may gamble the
real evidence, with a potential setback in the quality of care.
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